Incredible work by David Ouyang, MD as usual

Great to present data from TargetHTN trial of lorundrostat for treatment of uncontrolled hypertension AHAMeetings with #simpub in JAMA . jamanetwork.com/journals/jama/… Thanks to co-authors, 𝙼𝚊𝚝𝚝 𝙻𝚞𝚝𝚑𝚎𝚛 Anand Vaidya #Hypertension23 Cleveland Clinic ClevelandClinicNews

Hot off the press! Ashish Sarraju & Steven Nissen review the clinical evidence for atherosclerotic plaque stabilization and regression: rdcu.be/dvarz Cleveland Clinic Heart, Vascular & Thoracic

.Ashish Sarraju & S. Nissen discuss the evidence surrounding atherosclerotic plaque stabilization & regression as important clinical surrogates, and advancing therapeutic development nature.com/articles/s4156… Nature Reviews Cardiology

Aspirin for primary prevention of cardiovascular disease has been shown to cause more bleeding than benefit in randomized trials over the past 5 years. But it's still being taken by 1 of 3 older Americans. acpjournals.org/doi/full/10.73… Annals of Int Med Mohak Gupta Ashish Sarraju

Jennifer's LDL cholesterol was more than three times the normal range. It's known as "bad" cholesterol because it can block arteries in the heart. Jennifer has a genetic condition called FH. Now she's using her diagnosis to help others. #FHAwarenessDay bit.ly/47DD40S

Grateful to Jennifer sharing her journey with the diagnosis of FH. More work awaits to improve awareness, diagnosis, and management. Resources from the Family Heart Foundation are invaluable! #FHawarenessday Josh Knowles Fatima Rodriguez Cleveland Clinic Heart, Vascular & Thoracic Samir Kapadia

1/n We are excited to announce EchoPrime – the first echocardiography AI model capable of evaluating a full transthoracic echocardiogram study, identify the most relevant videos, and produce a comprehensive interpretation! Great work lead by Milos Vukadinovic, EchoPrime is the largest

1/ Now in JACC Journals: The Coming AI Revolution in Clinical Trials. euan ashley Nigam Shah Ashish Sarraju Kevin Schulman Robert Harrington Kenneth Mahaffey sciencedirect.com/science/articl… #JACC Stanford Medicine Stanford Department of Medicine Stanford Center for Clinical Research

And a randomized trial The Lancet with this CETP drug and ezetimibe combination thelancet.com/journals/lance…

Exciting day with more obicetrapib data for at ⁦⁦European Atherosclerosis Society⁩ with publications in ⁦NEJM⁩ and ⁦The Lancet⁩ ⁦John Kastelein⁩ ⁦Prof Kausik Ray FMedSci⁩ ⁦Michael Davidson MD⁩ ⁦Adam Nelson⁩ ⁦Julie Butters⁩ ⁦Monash Victorian Heart Institute⁩ ⁦NewAmsterdam Pharma Corporation⁩

Two late-breaker clinical trials on Obicetrapib presented today at EAS Congress. 1st, by Steven Nissen. Note that this study evaluates a fixed-dose combination of obicetrapib/ezetimibe in pts treated with maximally tolerated doses of statins. #EASCongress2025 John Kastelein

🚨Breaking news from #EASCongress2025 🚨 Obicetrapib/ezetimibe combo therapy nearly halved LDL at 84 days for patients with ASCVD or at high risk for it already taking maximally tolerated lipid-lowering therapy. EAS Congress Ashish Sarraju #cardiology healio.com/news/cardiolog…

Congratulations to my friend and colleague, Ashish Sarraju , and the team at C5Research (Cleveland Clinic Heart, Vascular & Thoracic ) on completing and publishing the TANDEM trial demonstrating the lipid lowering efficacy of obicetrapib-ezetimibe FDC thelancet.com/journals/lance…

The results of the TANDEM trial have been published in The Lancet The Lancet, simultaneously with their presentation at the #EASCongress2025! Read the full article here: doi.org/10.1016/S0140-… Ashish Sarraju Steve Nicholls John Kastelein EAS Congress European Atherosclerosis Society

Lowering your LDL cholesterol can be crucial for managing heart disease. A new drug combination lowered it by nearly half in a new clinical trial. Ashish Sarraju explains the findings. Read more: cle.clinic/434bvMm

Atherosclerotic cardiovascular disease contributes substantially to the global burden of cardiovascular disease. A new trial suggests promise for broadening the therapeutic landscape for patients with pre-existing or high risk for ASCVD. Find out more: hubs.li/Q03mW6MF0

The BROADWAY trial assesses the safety and efficacy of obicetrapib among patients at high risk for cardiovascular events. Get more details ➡️ bit.ly/4mmYQx6 #CardioX

Carotid web? Novel agents for stroke prevention? Interesting case discussions? We got it all covered at Cleveland Clinic MD Cerebrovascular Center Innovations in Cerebrovascular Care Conference 2025! ccfcme.org/iicc Thank you to our presenters @MariaSokolaMD Ashish Sarraju